Public, private partners in a brave new world
By North Jersey Media Group,
North Jersey Media Group
| 06. 22. 2005
There's a lot riding on the promise of biotechnology.
State officials say investing in the emerging medical science will improve New Jersey's balance sheet.
Scientists tout stem cells and other biotech research as the foundation of a whole new world of medicine, a world where the lame could walk and the old could live without debilitation.
For the sick and their loved ones, there is hope where there was none.
During the preparation of this series, The Record heard from dozens of national experts in medicine, science, commerce and government. There was plenty of divergence in their opinions.
But when asked to take the big view, almost all saw a role for both government and the private sector in the quest to turn the promise of biotech into the reality of better health.
Collectively, they offer a few simple guideposts that citizens and their elected representatives might consider when trying to assess how well the partnership is going.
Be patient
Abraham Abuchowski is a former Rutgers scientist who co-founded the New Jersey-based biotech Enzon in the 1980s. He now runs...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...